These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35728643)

  • 1. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis.
    Yang M; Li T; Jiang L; Wang Y; Tran C; Ao G
    J Infect; 2022 Oct; 85(4):e122-e124. PubMed ID: 35728643
    [No Abstract]   [Full Text] [Related]  

  • 2. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.
    Lee S; Lee SO; Lee JE; Kim KH; Lee SH; Hwang S; Kim SW; Chang HH; Kim Y; Bae S; Kim AS; Kwon KT
    Int Immunopharmacol; 2022 May; 106():108570. PubMed ID: 35168079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
    Lee JY; Lee JY; Ko JH; Hyun M; Kim HA; Cho S; Lee YD; Song J; Shin S; Peck KR
    Front Immunol; 2021; 12():772320. PubMed ID: 34899724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regdanvimab: First Approval.
    Syed YY
    Drugs; 2021 Dec; 81(18):2133-2137. PubMed ID: 34724174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
    Markina UA; Fomina DS; Lebedkina MS; Kruglova TS; Chernov AA; Zagrebneva AI; Mutovina ZY; Karaulov AV; Alexeeva EI; Lysenko MA
    Ter Arkh; 2022 Jun; 94(5):675-682. PubMed ID: 36286968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.
    Park S; Je NK; Kim DW; Park M; Heo J
    J Korean Med Sci; 2022 Apr; 37(13):e102. PubMed ID: 35380027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
    Marcec R; Dodig VM; Likic R
    J Infect; 2023 Jan; 86(1):66-117. PubMed ID: 36341992
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.
    Ao G; Li T; Wang Y; Tran C; Qi X
    J Infect; 2022 Jul; 85(1):e10-e12. PubMed ID: 35461909
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
    Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
    Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.
    Jang YR; Oh YJ; Kim JY
    Int J Infect Dis; 2023 May; 130():94-100. PubMed ID: 36623794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.
    Ryu DK; Kang B; Noh H; Woo SJ; Lee MH; Nuijten PM; Kim JI; Seo JM; Kim C; Kim M; Yang E; Lim G; Kim SG; Eo SK; Choi JA; Song M; Oh SS; Chung HY; Tijsma AS; van Baalen CA; Kwon KS; Lee SY
    Biochem Biophys Res Commun; 2021 Nov; 578():91-96. PubMed ID: 34547629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased
    Kim H; Jang YR; Lee JY; Ko JH; Lee JY; Cho S; Lee YD; Song J; Hyun M; Kim HA; Hwang S; Ryou S; Na YJ; Lee JY; Lee C; Lee NY; Shin S; Kwon KT; Kim JY; Peck KR
    Front Cell Infect Microbiol; 2023; 13():1192512. PubMed ID: 37256107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
    Miyazato Y; Yamamoto K; Nakaya Y; Morioka S; Takeuchi JS; Takamatsu Y; Maeda K; Kimura M; Sugiura W; Mitsuya H; Yano M; Ohmagari N
    J Infect Chemother; 2022 Jul; 28(7):991-994. PubMed ID: 35337728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Saultier P; Ninove L; Szepetowski S; Veneziano M; Visentin S; Barlogis V; Saba Villarroel PM; Amroun A; Loosveld M; de Lamballerie X; Chambost H
    Br J Haematol; 2022 Jan; 196(1):e1-e3. PubMed ID: 34337739
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
    Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sotrovimab in controlling SARS-CoV-2 infection].
    Płusa T
    Pol Merkur Lekarski; 2022 Feb; 50(295):48-50. PubMed ID: 35278299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 20. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.
    Zuo L; Ao G; Wang Y; Gao M; Qi X
    J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34534563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.